References:
1. Harvey HA, Cream LR. Biology of bone metastases: causes and consequences. Clin Breast Cancer. 2007;7(suppl 1):S7-S13. 2. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090. 3. Kinnane N. Burden of bone disease. Eur J Oncol Nurs. 2007;11(suppl):S28-S31. 4. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676. 5. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321. 6. Minami H, Kohno N, Aogi K, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. Presented at: 29th Congress of the European Society of Medical Oncology; October 29-November 2, 2004; Vienna, Austria. Abstract 194P. 7. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744. 8. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.9. Lipton A. Future treatment of bone metastases. Clin Cancer Res. 2006;12 (suppl 20):6305s-6308s. 10. Keller ET, Dai J, Escara-Wilke J, et al. New trends in the treatment of bone metastasis. J Cell Biochem. 2007;102:1095-1102.
11. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13. 12. Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease. Presented at: International Bone & Mineral Society Davos Workshops; March 9-14, 2008; Davos, Switzerland. Abstract 199. 13. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962-969. 14. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882. 15. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumours: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621. 16. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumours and bone metastases: analysis of a National Medical claims database. Cancer. 2008;113:1438-1445. 17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. V.2.2008. http://www.nccn.org. Accessed March 26, 2008. 18. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057.
